Suhasini Iyer Selected Research

allotrap

9/2005	Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model.
7/2004	RDP58, a novel immunomodulatory peptide, ameliorates clinical signs of disease in the Lewis rat model of acute experimental autoimmune encephalomyelitis.
12/2003	Attenuation of aortic graft arteriosclerosis by systemic administration of Allotrap peptide RDP58.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Suhasini Iyer Research Topics

Disease

7	Neoplasms (Cancer) 01/2021 - 11/2015
2	Cytokine Release Syndrome 01/2021 - 01/2021
2	Asthma (Bronchial Asthma) 11/2012 - 07/2010
2	Inflammation (Inflammations) 09/2005 - 12/2003
1	Prostatic Neoplasms (Prostate Cancer) 01/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021
1	Body Weight (Weight, Body) 01/2011
1	Immune System Diseases (Immune Disorders) 12/2007
1	Dermatitis 09/2005
1	Psoriasis (Pustulosis Palmaris et Plantaris) 09/2005
1	Autoimmune Diseases (Autoimmune Disease) 09/2005
1	Contact Dermatitis (Eczema, Contact) 09/2005
1	Atopic Dermatitis (Atopic Eczema) 09/2005
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 07/2004
1	Multiple Sclerosis 07/2004
1	Arteriosclerosis 12/2003
1	Necrosis 12/2003
1	Reperfusion Injury 01/2002

Drug/Important Bio-Agent (IBA)

4	CytokinesIBA 01/2021 - 09/2005
3	Monoclonal AntibodiesIBA 01/2016 - 12/2007
3	AntibodiesIBA 11/2015 - 12/2003
3	Peptides (Polypeptides)IBA 09/2005 - 12/2003
3	allotrapIBA 09/2005 - 12/2003
2	Bispecific AntibodiesIBA 05/2019 - 07/2010
2	Immunoconjugates (Immunoconjugate)IBA 03/2016 - 11/2015
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2005 - 12/2003
1	Muromonab-CD3 (Muromonab CD3)FDA Link 01/2021
1	Chimeric Antigen ReceptorsIBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	blinatumomabIBA 01/2021
1	Interleukin-2 (IL2)IBA 01/2021
1	Pharmaceutical PreparationsIBA 03/2016
1	Cytotoxins (Cytolysins)IBA 03/2016
1	Immune Checkpoint InhibitorsIBA 01/2016
1	LigandsIBA 01/2016
1	atezolizumabIBA 01/2016
1	Immunoglobulin E (IgE)IBA 11/2012
1	Immunoglobulin G (IgG)IBA 11/2012
1	Amino Acids FDA Link 11/2012
1	Omalizumab (Xolair)FDA Link 11/2012
1	anti-IgE antibodiesIBA 11/2012
1	Complementarity Determining Regions (Complementarity Determining Region)IBA 11/2012
1	IgE Receptors (Fc epsilon RI)IBA 07/2010
1	InterleukinsIBA 09/2005
1	Phorbol EstersIBA 09/2005
1	CarcinogensIBA 09/2005
1	Protein Kinase CIBA 09/2005
1	Interferon-gamma (Interferon, gamma)IBA 09/2005
1	Interleukin-6 (Interleukin 6)IBA 09/2005
1	Interleukin-12 (IL 12)IBA 09/2005
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 09/2005
1	Irritants (Vesicants)IBA 09/2005
1	Heme Oxygenase (Decyclizing) (Heme Oxygenase)IBA 12/2003
1	Complement System Proteins (Complement)IBA 12/2003
1	Heme Oxygenase-1IBA 01/2002

Therapy/Procedure

5	Therapeutics 01/2021 - 12/2003
1	Immunotherapy 01/2021
1	Castration 01/2021